Reverse Network Pharmacology-Based Identification of 20-Hydroxyecdysone and Its Inhibition of Glioblastoma Malignant Phenotypes Through the PI3K/AKT Pathway.

doi:10.31083/FBL52978

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Reverse Network Pharmacology-Based Identification of 20-Hydroxyecdysone and Its Inhibition of Glioblastoma Malignant Phenotypes Through the PI3K/AKT Pathway.

Frontiers in bioscience (Landmark edition) - 18 Aug 2026

Zhang Jinhui, Wei Chao, Wang Dongyan, He Renmi, Xiao Xiangdan, Xu Jianwei, Lu Junhou

Abstract excerpt

BACKGROUND: Glioblastoma is the most aggressive primary malignant brain tumor of the central nervous system and remains difficult to treat because of rapid progression, diffuse invasion, and frequent recurrence. This study aimed to identify a potential natural compound against glioblastoma using a reverse network pharmacology strategy and to investigate its anti-glioma effects and underlying mechanism. METHODS:...

Read the complete abstract on PubMed

Topics

Ecdysterone
Humans
Glioblastoma
Proto-Oncogene Proteins c-akt
Signal Transduction
Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Brain Neoplasms

Molecular Docking Simulation

Cell Line, Tumor

Network Pharmacology

Apoptosis

Cell Movement

Cell Proliferation

Gene Expression Regulation, Neoplastic

Molecular Dynamics Simulation

Cell Survival

Phenotype

Source

Open in PubMed

Identifiers

PMID: 42689980
DOI: 10.31083/FBL52978

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reverse Network Pharmacology-Based Identification of 20-Hydroxyecdysone and Its Inhibition of Glioblastoma Malignant Phenotypes Through the PI3K/AKT Pathway.PMID 42689980Read ↗

Molecular targets of vortioxetine mediating glioblastoma suppression revealed by gene and protein network analyses and molecular docking simulationsSemantic proximity Read ↗

Exploring the Therapeutic Mechanisms and Prognostic Targets of Biochanin A in Glioblastoma via Network Pharmacology and Bioinformatics AnalysisSemantic proximity Read ↗

Deciphering the Dose-Dependent Effects of Thymoquinone on Transcriptomic Changes and Cellular Proliferation in GlioblastomaSemantic proximity Read ↗

Exploring the therapeutic mechanisms and prognostic targets of Biochanin A in glioblastoma via integrated computational analysis and in vitro experimentsSemantic proximity Read ↗

Inhibition of Glioblastoma Growth by the Thiadiazolidinone Compound TDZD-8Semantic proximity Read ↗

Repurposing Ivermectin and ATRA as Potential Therapeutics for Glioblastoma MultiformeSemantic proximity Read ↗

The Role of Natural Products as Inhibitors of JAK/STAT Signaling Pathways in Glioblastoma TreatmentSemantic proximity Read ↗

Drug connectivity mapping and functional analysis reveals therapeutic small molecules that differentially modulate myelinationSemantic proximity Read ↗

Anti-angiogenic Potential of Trans-chalcone in an In Vivo Chick Chorioallantoic Membrane Model: An ATP Antagonist to VEGFR with Predicted Blood-brain Barrier PermeabilitySemantic proximity Read ↗

Exploring the Potentials of S4, A Selective Androgen Receptor Modulator, in Glioblastoma Multiforme TherapySemantic proximity Read ↗

Epiregulin enhances tumorigenicity by activating the ERK/MAPK pathway in glioblastomaSemantic proximity Read ↗

Estrogen Receptors as Molecular Targets of Endocrine Therapy for GlioblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.